Strategic Partnership between Geneart and Qiagen
Geneart AG (Entry Standard G6A, Frankfurt) and Qiagen N.V. (Prime Standard QIA, Frankfurt and QGEN, Nasdaq USA) are in their respective areas of specialisation in the manufacture of synthetic genes and gene libraries global technology and market leaders. Meanwhile Geneart has become one of the largest manufacturers of synthetic genes, which are essential for the development of new therapeutic agents and vaccines. Qiagen is one of the first Biotech companies and with 2700 employees in 30 locations worldwide, a leading provider of sample preparation and test technology of most biomolecules. The products are today standard in forensics, veterinary and foodstuff testing, pharmaceutical process control and in most laboratories. Unique is the product line “GeneGlobe”, the largest databank worldwide with testing for gene regulation and gene expression – so called “assays”, which are of particular importance for the development of new medications. The partnership between the companies has as a goal the artificial manufacturing of a complete collection of genes from mammals and representing these in a gene bank. Further developments in this cooperation should mean significant improvement in the production of human proteins and thereby speed the development of medicines.
For more information see: